Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantifica
By: Angelina Cistaro, Natale Quartuccio, Alireza Mojtahedi, Piercarlo Fania, Pier Luigi Filosso, Alfredo Campenni, Umberto Ficola and Sergio Baldari
Open Access
|Jul 2013References
- 1. WHO Department of Gender, Women and Health.Geneva: World Health Organization; January 2004. p. 8.
- 2. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.2003;2500-7.
- 3. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer.2004;119-42.
- 4. Hellwig D, Baum RP, Kirsch C. FDG PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review.2009;59-69.
- 5. Vansteenkiste J, Fisher BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review.2004;531-40.
- 6. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.2012;559-66.
- 7. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J,. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.2008;130-4.
- 8. Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumour volume of ¹⁸F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer.2011;1628-35.
- 9. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, et al. (18) F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.2011;1684-9.
- 10. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in earlystage non-small cell lung cancer.1995;466-72.
- 11. Gümüştaş S, Inan N, Akansel G, Ciftçi E, Demirci A, Ozkara SK. Differentiation of malignant and benign lung lesions with diffusion-weighted MR imaging.2012;106-13.
- 12. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management.2007;56-63.
- 13. Andrade RS, Odell DD, D’Cunha J, Maddaus MA. Endobronchial ultrasonography (EBUS)-Its role in staging of non-small cell lung cancer and who should do it?2012;S9-S13.
- 14. American Joint Committee on Cancer.. 7th edition. New York: Springer; 2010. p. 299-324.
- 15. Eisenhauera EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).2009;228-47.
- 16. Beadsmoore CJ, Screton NJ. Classification, staging and prognosis of lung cancer.2003;8-17.
- 17. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET.1999;1771-7.
- 18. Huang SC. Anatomy of SUV. Standardized uptake value.2000;643-6.
- 19. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV Measurements.2010;1043
- 20. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.2010;181-200.
- 21. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.2005;151-9.
- 22. Van Baardwijk A, Dooms C, Van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.2007;1392-8.
- 23. Sasaki R, Komaki R, Macapinlac H. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.2005;1136-43.
- 24. Jeong HJ, Min JJ, Park JM, Kim BT, Jeong JM, Lee DS, et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer.2002;865-70.
- 25. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.2004;3255-60.
- 26. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role.2007;3255-63.
- 27. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group.1999;3201-6.
- 28. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer.2008;819-23.
Language: English
Page range: 219 - 223
Published on: Jul 30, 2013
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2013 Angelina Cistaro, Natale Quartuccio, Alireza Mojtahedi, Piercarlo Fania, Pier Luigi Filosso, Alfredo Campenni, Umberto Ficola, Sergio Baldari, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.